インブルビカ(イブルチニブ)の世界市場:医薬品インサイト・市場予測

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DELV20JU239)
◆英語タイトル:Imbruvica (ibrutinib) - Drug Insight and Market Forecast - 2030
◆発行会社/調査会社:DelveInsight
◆商品コード:DELV20JU239
◆発行日:2020年7月
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆産業分野:製薬
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後2営業日)
◆販売価格オプション(消費税別)
Single User(239名様閲覧)USD2,750 ⇒換算¥302,500見積依頼/購入/質問フォーム
Three UserUSD4,125 ⇒換算¥453,750見積依頼/購入/質問フォーム
Site LicenseUSD5,500 ⇒換算¥605,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[インブルビカ(イブルチニブ)の世界市場:医薬品インサイト・市場予測]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

“Imbruvica (ibrutinib) – Drug Insight and Market Forecast – 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Imbruvica (ibrutinib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Scope of the report
The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
Elaborated details on regulatory milestones and other development activities have been provided in this report.
The report also highlights the drug marketed details across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around Imbruvica (ibrutinib).
The report contains historical and forecasted sales for Imbruvica (ibrutinib) till 2030.
Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
The report also features the SWOT analysis with analyst insights and key findings of Imbruvica (ibrutinib).
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Imbruvica (ibrutinib) Analytical Perspective by DelveInsight

In-depth Imbruvica (ibrutinib) Market Assessment
This report provides a detailed market assessment of Imbruvica (ibrutinib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Imbruvica (ibrutinib) Clinical Assessment
The report provides the clinical trials information of Imbruvica (ibrutinib) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
In the coming years, the market scenario for Imbruvica (ibrutinib) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Imbruvica (ibrutinib) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Other approved products for the disease are giving market competition to Imbruvica (ibrutinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Imbruvica (ibrutinib).
Our in-depth analysis of the sales data of Imbruvica (ibrutinib) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Imbruvica (ibrutinib) in the market.
Key Questions
What is the prescribed dosage and strengths of Imbruvica (ibrutinib) are available in the market?
What are the common adverse reactions or side effects of Imbruvica (ibrutinib)?
What is the product type, route of administration and mechanism of action of Imbruvica (ibrutinib)?
What are the chemical specifications of Imbruvica (ibrutinib)?
How are the clinical trials diversified on the basis of the trial status?
What is the history of Imbruvica (ibrutinib), and what is its future?
What are the marketed details of Imbruvica (ibrutinib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
How many patents have been granted to Imbruvica (ibrutinib) and when these patents will get expire?
What are the pros (benefits) and cons (disadvantages) of Imbruvica (ibrutinib)?
In which countries Imbruvica (ibrutinib) got approval and when it gets launched?
What are the clinical trials are currently ongoing for Imbruvica (ibrutinib)?
How the safety and efficacy results determined the approval of Imbruvica (ibrutinib)?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Imbruvica (ibrutinib) development?
What are the key designations that have been granted to Imbruvica (ibrutinib)?
What is the historical and forecasted market scenario of Imbruvica (ibrutinib)?
How is the market trend of Imbruvica (ibrutinib) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
What are the other approved products available and how these are giving competition to Imbruvica (ibrutinib)?
Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

*** レポート目次(コンテンツ)***

1. Product Overview

1.1. Indication

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4.1 Dosage Forms and Strengths

1.4. Route of Synthesis

1.5. Pharmacology

1.4.2 Pharmacodynamics

1.4.3 Pharmacokinetics

1.6. Adverse Reactions

1.7. Product Snapshot

1.8. Development Milestones of Imbruvica (ibrutinib)

1.9. Marketed Details

1.4.4 United States

1.4.5 Europe

1.4.6 Japan

1.10. Patent Details

2. SWOT Analysis

2.1. Analyst Views

3. Regulatory Milestones

3.1. Approvals

3.2. Research and Development

3.3. Clinical Trials Information

3.4. Safety and Efficacy

3.5. Product Developmental Activities

4. Market Assessment

4.1. 7MM Market Analysis

4.2. United States

4.3. Europe

4.4. Japan

4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

7.1. Report Purchase Options

Table 1: Imbruvica (ibrutinib), Description

Table 2: Imbruvica (ibrutinib), Trial Diversification

Table 3: Imbruvica (ibrutinib), Marketed Details United States

Table 4: Imbruvica (ibrutinib), Marketed Details Europe

Table 5: Imbruvica (ibrutinib), Marketed Details Japan

Table 6: Patent Details: Imbruvica (ibrutinib)

Table 7: Imbruvica (ibrutinib), Clinical Trial Description, 2020

Table 8: Safety and Efficacy Results for Imbruvica (ibrutinib)

Table 9: Imbruvica (ibrutinib), 7MM Market Size from 2017 to 2030 (in Million USD)

Table 10: Imbruvica (ibrutinib), US Market Size from 2017 to 2030 (in Million USD)

Table 11: Imbruvica (ibrutinib), EU Market Size from 2017 to 2030 (in Million USD)

Table 12: Imbruvica (ibrutinib), EU5 Market Size from 2017 to 2030 (in Millions USD)

Table 13: Imbruvica (ibrutinib), Japan Market Size from 2017 to 2030 (in Million USD)

Table 14: Market Competitors

Table 15: Emerging Therapies



List of Figures:

Figure 1: The Development Timeline of Imbruvica (ibrutinib)

Figure 2: Patent Details, Imbruvica (ibrutinib)

Figure 3: Imbruvica (ibrutinib), 7MM Market Size from 2017 to 2030 (in Million USD)

Figure 4: Imbruvica (ibrutinib), US Market Size from 2017 to 2030 (in Millions USD)

Figure 5: Imbruvica (ibrutinib), EU Market Size from 2017 to 2030 (in Millions USD)

Figure 6: Imbruvica (ibrutinib), EU5 Market Size from 2017 to 2030 (in Millions USD)

Figure 7: Imbruvica (ibrutinib), Japan Market Size from 2017 to 2030 (in Millions USD)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • ニフェジピンの世界市場予測2018-2023
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Nifedipine market for 2018-2023. Nifedipine is a drug that belongs to the class of calcium channel blocker, which interrupts the movement of calcium in the walls of the arter …
  • 超音波流速計の世界市場:販売動向2017
    Notes:Sales, means the sales volume of Ultrasonic Flow Meters Revenue, means the sales value of Ultrasonic Flow Meters This report studies sales (consumption) of Ultrasonic Flow Meters in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/cou …
  • インダッシュナビゲーションシステムの北米市場
    KEY FINDINGSThe North America in-dash navigation system market is expected to flourish over the forecast period of 2018-2026 by growing with a CAGR of 12.58%. Increasing sales of passenger cars, along with the rising disposable income are factors which are positively impacting the growth of the in-d …
  • 仮想センサーの世界市場予測(~2023年)
    Potential reduction in the time and cost required for product development through the implementation of a virtual sensor to drive the virtual sensors marketThe global virtual sensors market size is expected to grow from USD 235 million in 2018 to USD 910 million by 2023, at a Compound Annual Growth …
  • ミネラル化粧品の世界市場:製品別(フェイス製品、リップ製品、アイ製品)、流通経路別、地域別(北米、ヨーロッパ、APAC、CSA、MEA)
    The global mineral cosmetics market size is expected to reach USD 4.3 billion by 2025, expanding at a CAGR of 5.3%, according to a new report by Grand View Research, Inc. Shifting consumer preference for organic and natural beauty products is driving the market across the globe. Increasing conscious …
  • 特殊プロパンツの世界市場
    In this report, the global Specialty Proppant market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million …
  • 耐火ダクトの世界市場
    Fire Rated Ducts Market Forecast till 2026 Market Synopsis: According to Market Research Future Analysis, the Global Fire-rated ducts Market is anticipated to register substantial market growth during the review period. The fire ducts assure the safety of fire compartmentation; they are used to prev …
  • 種子の世界市場2018-2022
    About Seeds A seed is an embryonic plant enclosed in a protective layer. The formation of seed is part of the process of reproduction in plants. Technavio’s analysts forecast the global seeds market to grow at a CAGR of 9.22% during the period 2018-2022. [Covered in this report] The report covers th …
  • 神経インターベンション装置の世界市場見通し2017-2023
    According to Stratistics MRC,the Global Interventional Neurology Devices Market is accounted for $1.89 billion in 2016 and expected to grow at a CAGR of 10.3% to reach $3.76 billion by 2023. The market factors such as growth due to obesity and aged population, rising frequency for hemorrhagic and is …
  • 止血剤パウダーの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)
    When blood vessel walls are disrupted during surgeries, there are occurrences of blood loss, which needs to get coagulated. This process of blood clot formation at the site of injury is known as hemostasis. Hence, hemostats offer temporary blockage by forming blood clot to control bleeding. [Scope o …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DELV20JU239 )"インブルビカ(イブルチニブ)の世界市場:医薬品インサイト・市場予測" (英文:Imbruvica (ibrutinib) - Drug Insight and Market Forecast - 2030)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。